semaglutide 2.0 mg approval Oral Shows Promise in Adolescents with Type 2 Diabetes Novo Nordisk Receives FDA Approval

Are there side effects of Ozempic and Mounjaro that clinical trials missed

The apparent increased risk of NAION must be considered in context, as GLP-1 receptor drugs have provided considerable benefit to millions of users, including an increased chance of improved management of type 2 diabetes, substantial reduction in body weight, substantially improved morbidity and mortality of major adverse cardiovascular events and even reduced addictive behaviors, they noted

In clinical trials, people with Type 2 diabetes lost less weight than people without diabetes, but thats likely related to other factors, Dr

A temporary dose reduction or a different formulation may suit you better